Navigation Links
Bayer HealthCare Provides Nearly $2.5 Million to Advance Hemophilia Research and Patient Care
Date:7/28/2011

Philadelphia, for "The role of EPCR on FVIIa-mediated hemostasis"

Since its founding in 2002, BHAP has awarded nearly 200 grants, totaling more than $22.5 million, to researchers and caregivers from 29 countries.  This support has resulted in more than 290 scientific abstracts, publications and presentations by awardees to date.

"BHAP, now in its ninth year, continues to attract high-quality applicants and awardees who are focused on advancing hemophilia treatment and patient care. Through such research, we hope to advance scientific understanding and positively affect the diagnosis and treatment of hemophilia and related bleeding disorders," said Prof. Johannes Oldenburg, chairman of the BHAP Grants, Review and Awards Committee and Head of the Institute of Experimental Haematology and Transfusion Medicine at University Clinic Bonn.  

In addition to the BHAP award ceremony at this year's ISTH Congress, Bayer is also presenting data from globally sponsored studies and country-sponsored programs.  Seventeen studies will be presented, including seven oral presentations.

About the Bayer Hemophilia Awards Program

The Bayer Hemophilia Awards Program (BHAP) supports basic and clinical research and education in hemophilia. Through grants provided to early career investigators, fellows in training and other hemophilia care professionals, the program seeks to support the next generation of care and treatment options for people with hemophilia worldwide. Parties who wish to apply for the 2012 Bayer Hemophilia Awards should submit a letter of intent by November 30, 2011 to be considered. For complete information on the Program, award categories and electronic submission process, visit the Web site at bayer-hemophilia-awards.com.

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an in
'/>"/>

SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by AstraZeneca plc, ... an important drug for the treatment of schizophrenia. ... quetiapine was listed in the Catalogue of Drugs ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ) ... on China,s Ranibizumab Market, 2012-2019" report to their ... by CFDA to treat wet age- related macular degeneration ... Novartis, is available in the Chinese market. However, in ... the treatment of wet AMD in China ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... IRIDEX Corporation (NASDAQ: IRIX ) today announced that it ... closes on Thursday, November 3, 2011.  In ... with the investment community at 5:00 p.m. Eastern Time ... to discuss the results of the quarter and other business developments. ...
... A potentially groundbreaking approach to predicting cancer patient ... electronic version of Science Magazine.  The paper describing the ... Letai and colleagues at Boston,s Dana Farber Cancer Institute. ... of the cancer cell to respond to chemotherapies. This ...
Cached Medicine Technology:Groundbreaking Approach to Predicting Cancer Patients' Response to Treatment Featured in Science Magazine 2
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I ... from Miller Place, N.Y. "I specialize in manual therapy, and my invention will ... can be used for additional muscle dysfunction throughout the body." , They developed ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is a ... field in the military. All too often VA hospitals treat patients with harmful and ... the VA program over a decade ago, the reality is that only 10% of ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops ... seconds of unique footage that users can shrink and stretch in the Final Cut ... Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted ... it will be devoting an entire short segment to the subject of diabetes. Diabetes ... globe on a daily basis, but recent advancements in medical science may prove to ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... School of Medicine (BUSM) have shown that patients ... of their degree of adherence to antihypertensive medications. ... Hypertension could have an immediate impact ... held assumption. The BUSM researchers studied ...
... for PCV-7 vaccine supported by study findings , TUESDAY, ... will be relieved by new findings that show a ... against pneumonia and other infections. , The current recommended ... of three primary doses before the age of 6 ...
... women more likely to die, but questions remain , TUESDAY, ... cancer outcomes, with black women more likely to die from ... new research shows. , , For a quarter of a ... in certain cancers. The racial disparity "first emerged about 25 ...
... Texas, July 7 Perot Systems (NYSE: PER ... case studies highlighting the success of several of its healthcare ... process solutions. The videos feature the Perot Systems clients ... Pilgrim Health Care , and Northern Arizona Healthcare . ...
... ... a New Century (The Collaboration) announced today the availability of a ... savingsdrugcard.com provides a free drug card that will help all Arizonans ... card by visiting http://www.SavingsDrugCard.com and can immediately start saving ...
... suggests proton pump inhibitors could aggravate acid trouble , TUESDAY, ... heartburn and acid reflux may actually cause heartburn. , A ... found that treatment with a proton pump inhibitor (PPI) actually ... took the medication for eight weeks. , Although the ...
Cached Medicine News:Health News:Intensive management can improve blood pressure in non-adherent hypertensive patients 2Health News:Fewer Shots Could Still Protect Kids From Pneumonia 2Health News:New Clues to Race Gap in Breast Cancer Outcomes 2Health News:New Clues to Race Gap in Breast Cancer Outcomes 3Health News:Video: Perot Systems Unveils Series of Healthcare Video Case Studies 2Health News:Popular Prescription Drug Discount Card Now Available in Arizona Online 2Health News:Popular Prescription Drug Discount Card Now Available in Arizona Online 3Health News:Heartburn Drugs May Contribute to the Problem 2Health News:Heartburn Drugs May Contribute to the Problem 3
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
... technology is the first and ... patented digital sensor all ... sensor. Dolphin ONE™ sensors both ... in the sensor, resulting in ...
... Oil is a clear, colorless oil ... of the UV-VIS spectrum. Resolve is ... viscosity, is non-drying and non-hardening, and ... Resolve contains no PCBs, eliminating toxicity ...
Medicine Products: